Any current/future new fundraising through debt or equity?

No plans for raising debt were mentioned in the call; Beta Drugs Limited currently remains net debt-free with a surplus cash position. The derma plant CAPEX of around Rs. 30 crores is planned to be funded mainly through internal cash accruals. Future CAPEX for R&D, new injectable facility, and derma plant expansions will also be funded through internal accruals. Regarding equity, the company will issue slight bonus shares only for authorized capital requirements related to migration from SME to the main board, but no broad bonus share issuance or equity fundraising is planned. Overall, fundrai

Any current/future capex/capital investment/strategic investment?

Beta Drugs has recently added a new injectable facility with 2 lyophilizers and an additional Kilo lab line for small quantity, high-value APIs. No major CAPEX is planned in the next 1-2 years; future CAPEX will be funded from internal cash accruals. Plans for a dermatology plant with an estimated CAPEX of around Rs. 30-40 crores, expected to be completed in 1.5 to 2 years, funded mainly by internal accruals. A separate R&D block for technology transfer in API and formulation is planned on existing land. Long-term plan (after 3 years) to build a dedicated injectable facility targeting the US m

Future growth expectations in sales/revenue/volumes?

Beta Drugs Limited targets a revenue growth of 20%-25%, with ambitions to expand globally and take calculated risks for larger scale growth. The company aims to achieve Rs. 290+ crores revenue in FY24, exceeding the previous Rs. 280 crore target. The medium-term goal is to double revenue to Rs. 450 crores by FY26, considered 100% achievable. Strong growth is expected from NDDS product launches planned for December 2023 and ongoing R&D innovation. Exports are set for significant growth in 2-3 years with over 200 dossiers planned for filing globally, including LATAM, Asia, and Africa.

Future growth expectations in earnings/operating earnings/profits/EPS?

Beta Drugs expects to grow revenues at 20% to 25%, with a target of Rs. 450 crores by FY26, which is achievable and may be exceeded. EBITDA margin is anticipated to improve further due to strong R&D pipeline and differentiated offerings (NDDS, FTL, FFTL). The company is poised for 25% to 30% growth over the next few years, driven by own brands, exports, OEM, and API segments. Earnings growth will benefit from expansion in semi-regulated and regulated export markets (LATAM, Asia, Africa). Dermatology business aims for Rs. 50 crores sales in 3-4 years, expected to boost company margins.

Current/ Expected Orderbook/ Pending Orders?

As of the call, there is no explicit mention of a quantified current or expected order book value or pending orders. The company has signed over 20 agreements with international partners in the last 6 months, indicating a growing order pipeline for export markets. Plans to file over 200 dossiers in the next 2-3 years to support new product registrations and future orders. Strong interest from foreign clients for the differentiated product portfolio suggests healthy order inflows going forward. Capacity utilization on oral and liquid sides is between 40% to 80%, supporting potential revenue up

Beta Drugs LtdQ2 FY24Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,849.7P/E: 45.0Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Beta Drugs Limited targets a revenue growth of 20%-25%, with ambitions to expand globally and take calculated risks for larger scale growth.
The company aims to achieve Rs. 290+ crores revenue in FY24, exceeding the previous Rs. 280 crore target.
The medium-term goal is to double revenue to Rs. 450 crores by FY26, considered 100% achievable.
Strong growth is expected from NDDS product launches planned for December 2023 and ongoing R&D innovation.
Exports are set for significant growth in 2-3 years with over 200 dossiers planned for filing globally, including LATAM, Asia, and Africa.
Expansion in dermatology products targets Rs. 50 crores sales in 3-4 years, with a new plant expected in 1.5-2 years.
Continued capacity utilization improvements and selective CAPEX from internal accruals will support volume increases without immediate need for large external investments.

Margin guidance

Category 1

Beta Drugs expects to grow revenues at 20% to 25%, with a target of Rs. 450 crores by FY26, which is achievable and may be exceeded.
EBITDA margin is anticipated to improve further due to strong R&D pipeline and differentiated offerings (NDDS, FTL, FFTL).
The company is poised for 25% to 30% growth over the next few years, driven by own brands, exports, OEM, and API segments.
Earnings growth will benefit from expansion in semi-regulated and regulated export markets (LATAM, Asia, Africa).
Dermatology business aims for Rs. 50 crores sales in 3-4 years, expected to boost company margins.
Export business margins are higher than domestic business, with international expansion to countries like Brazil, Mexico, South Africa.
Operating profits and EPS expected to grow robustly, supported by capacity utilization improvements and limited CAPEX needs for next 1-2 years.
Overall, Beta Drugs aims for sustained margin and profit expansion alongside strong top-line growth.

See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No plans for raising debt were mentioned in the call; Beta Drugs Limited currently remains net debt-free with a surplus cash position.
The derma plant CAPEX of around Rs. 30 crores is planned to be funded mainly through internal cash accruals.
Future CAPEX for R&D, new injectable facility, and derma plant expansions will also be funded through internal accruals.
Regarding equity, the company will issue slight bonus shares only for authorized capital requirements related to migration from SME to the main board, but no broad bonus share issuance or equity fundraising is planned.
Overall, fundraising through external debt or equity is not planned in the near term; the company prefers to fund growth and expansions internally.

Order book

Yes

As of the call, there is no explicit mention of a quantified current or expected order book value or pending orders.
The company has signed over 20 agreements with international partners in the last 6 months, indicating a growing order pipeline for export markets.
Plans to file over 200 dossiers in the next 2-3 years to support new product registrations and future orders.
Strong interest from foreign clients for the differentiated product portfolio suggests healthy order inflows going forward.
Capacity utilization on oral and liquid sides is between 40% to 80%, supporting potential revenue up to Rs. 500 crores with existing capacity.
No immediate CAPEX planned for expansion — growth to be driven through internal cash accruals and existing capacity.
New product launches (including 2 NDDS products by December 2023) expected to bolster order inflows, especially domestically.

See what Beta Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Beta Drugs has recently added a new injectable facility with 2 lyophilizers and an additional Kilo lab line for small quantity, high-value APIs.
No major CAPEX is planned in the next 1-2 years; future CAPEX will be funded from internal cash accruals.
Plans for a dermatology plant with an estimated CAPEX of around Rs. 30-40 crores, expected to be completed in 1.5 to 2 years, funded mainly by internal accruals.
A separate R&D block for technology transfer in API and formulation is planned on existing land.
Long-term plan (after 3 years) to build a dedicated injectable facility targeting the US market.
CAPEX is an ongoing process to boost capacity and productivity as opportunities arise; current capacity can support revenue up to Rs. 500 crores without additional capex.

Track Beta Drugs Ltd — get its next earnings analysis in your feed

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBeta Drugs Ltd

Rev 2Mar 1

See where Beta Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →